A detailed history of Quest Partners LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Quest Partners LLC holds 25 shares of AKRO stock, worth $882. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25
Previous 12,609 99.8%
Holding current value
$882
Previous $296 Million 99.76%
% of portfolio
0.0%
Previous 0.04%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$21.45 - $29.34 $269,926 - $369,214
-12,584 Reduced 99.8%
25 $717,000
Q2 2024

Aug 06, 2024

BUY
$18.31 - $24.62 $229,827 - $309,030
12,552 Added 22021.05%
12,609 $296 Million
Q1 2024

May 09, 2024

SELL
$17.76 - $31.18 $56,157 - $98,591
-3,162 Reduced 98.23%
57 $1.44 Million
Q4 2023

Feb 09, 2024

BUY
$11.38 - $50.33 $36,632 - $162,012
3,219 New
3,219 $75.2 Million

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.64B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Quest Partners LLC Portfolio

Follow Quest Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quest Partners LLC with notifications on news.